There’s no shortage of prominent investors saying the stock market is in for a correction in the coming months.
With inflation at a 30-year high and a number of companies carrying share prices that could be considered unrealistic, the anxiety makes sense.
But what if the doom-and-gloom crowd is wrong?
Brian Belski, BMO Capital Markets’ chief investment strategist, says the S&P 500 could be sitting at around 5,300 by the end of 2022 — a 17% rise from current levels.
Belski doesn’t see inflation as a long-term problem to strategize around. He believes robust company earnings and support by the Federal Reserve will keep the market rolling.
"The fundamental construct of the United States stock market is in wonderful condition,” Belski told Business Insider.
Here are three stocks BMO expects to outperform a healthy market next year. You may be able to get a piece of them with a few extra pennies.
1. Pfizer (PFE)
It was just last week that BMO Capital initiated an “outperform” rating for pharmaceutical giant Pfizer, signaling that the company could outdo many competitors next year.
Pfizer’s share price is hovering around $53. BMO has projected it to hit $60.
Pfizer’s vaccine business is the obvious draw here, with COVID-generated revenue likely to continue rolling in over the next year. But the company’s solid financials and pipeline of new products should help it maintain the momentum it has built this year.
Pfizer just wrapped up a wild third quarter that saw revenues hit $24.1 billion — 134% higher than during the same period last year.
Year-to-date, Pfizer stock has risen 44%. It’s gained over 4% in the last week alone.
2. Palo Alto Networks (PANW)
BMO already bestowed an “outperform” rating on Palo Alto Networks after the cybersecurity firm released its Q1 earnings. Not only does that rating still hold, but BMO recently raised its price target for the company from $560 to $615.
Everything seems to be trending in the right direction for the company.
Its Q3 revenue beat analyst expectations by about $50 million, and was 28% higher year over year. Inflation has allowed Palo Alto to increase prices, and the steady growth of the cloud computing space means an increasing number of businesses should require its technology.
Palo Alto Networks is projecting revenue of around $5.3 billion for 2022. That rosy outlook has helped lift the company’s share price by about 48% since Aug. 23.
3. Alphabet (GOOGL)
Similar to Palo Alto Networks, BMO had already identified Alphabet, Google’s parent company, as an “outperform” candidate prior to the release of its third quarter earnings report. BMO then swiftly upped its target price for Alphabet from $3,000 to $3,200 per share.
Alphabet’s Q3 performance was predictably colossal. The $18.9 billion in profit marked the company’s fifth record-breaking quarter in a row. The revenue brought in during the third quarter, $65.1 billion, was almost $19 billion higher than in the same period last year.
Revenue from search and YouTube advertising continues to rise, as does the cash coming in from Google Cloud. Alphabet makes it difficult for investors to know how its Pixel phones and Android operating system are faring among consumers, but when your profits are increasing by 69% year over year, there’s not much reason to nitpick.
Even if the market grows, this investment might grow faster
No one really knows if the stock market is going to continue barreling ahead. It could run out of steam tomorrow.
Either way, now might be the time to consider diversifying your portfolio with real assets, which can insulate you from market turmoil and inflation.
One of those assets taking up increasing space in modern portfolios is contemporary art, which has outperformed the S&P 500 almost every year since 1995.
You don’t need millions of dollars to invest in rapidly appreciating works by artists like Banksy, Andy Warhol or Jean-Michel Basquiat, whose never-seen-before painting owned by rapper Jay-Z was the backdrop of his recent Tiffany & Co. ad with Beyonce.
A popular new app allows you to purchase shares in a variety of masterpieces for a fraction of the cost.
This article provides information only and should not be construed as advice. It is provided without warranty of any kind.